SlideShare a Scribd company logo
1 of 48
Download to read offline
TUBERCULOSIS
CONTENTS:
•INTRODUCTION
•EPIDEMIOLOGY
•CAUSES
•PATHOGENESIS
•DIAGNOSIS
•TREATMENT
 Tuberculosis or TB is a common and
often deadly infectious disease caused
by mycobacteria, usually Mycobacterium
tuberculosis in humans.
 Tuberculosis usually attacks
the lungs but can also affect other parts
of the body.
 The classic symptoms are
a chronic cough with blood-tinged
sputum, fever, night sweats, and weight
loss.
 The primary cause of TB, Mycobacterium tuberculosis ,
is a small aerobic non-motile bacillus.
 The M. tuberculosis complex includes four other TB-
causing mycobacteria: M. bovis, M. africanum, M.
canetti and M. microti.
 M. africanum is not widespread, but in parts of Africa
it is a significant cause of tuberculosis.
 It is currently estimated that 1/2 of the
world's population (3.1 billion) is infected
with Mycobacterium tuberculosis.
Mycobacterium avium complex is associated
with AIDS related TB.
 The proportion of people who become sick
with tuberculosis each year is stable or
falling worldwide but, because of
population growth, the absolute number
of new cases is still increasing.
EPIDEMIOLOGY:
 In 2007 there were an estimated 13.7 million chronic
active cases, 9.3 million new cases, and 1.8 million
deaths, mostly in developing countries.
 The distribution of tuberculosis is not uniform across
the globe; about 80% of the population in many Asian
and African countries test positive in tuberculin tests,
while only 5-10% of the US population test positive.
Per 1,000,00
10 - 24
< 10
25 - 49
50 - 99
100 - 299
300 or more
No estimate Highest estimated
TB rates per capita
were in Africa
 Pulmonary tuberculosis is a disease
of respiratory transmission, Patients
with the active disease (bacilli) expel
them into the air by:
 coughing,
 sneezing,
 shouting,
 or any other way that will expel
bacilli into the air
Transmission is dependent on closeness and time of
contact
Transmission:
 Once inhaled by a tuberculin free person, the
bacilli multiply 4 -6 weeks and spreads
throughout the body. The bacilli implant in areas
of high partial pressure of oxygen:
 lung
 renal cortex
 reticuloendothelial system
 When the disease becomes active, 75% of the cases
are pulmonary TB, that is, TB in the lungs.
 Symptoms include chest pain, coughing up blood,
and a productive, prolonged cough for more than
three weeks.
 Systemic symptoms include fever, chills, night
sweats, appetite loss, weight loss, pallor, and
often a tendency to fatigue very easily.
 In the other 25% of active cases, the infection moves
from the lungs, causing other kinds of TB, collectively
denoted extrapulmonary tuberculosis. This occurs
more commonly in immunosuppressed persons and
young children.
 Extrapulmonary infection sites include the pleura in
tuberculosis pleurisy, the central nervous system
in meningitis, the lymphatic system in scrofula of the
neck, the genitourinary system in urogenital
tuberculosis, and bones and joints in Pott's disease of
the spine.
Tuberculosis
Infection via inhalation of droplet nuclei.
↓
Transport of bacilli to terminal alveoli (especially lower
segments of lungs)
↓
Ingestion of organisms by macrophages followed by
multiplication within macrophages
↓
Transport of organisms to regional lymph nodes by infected
macrophages with continue multiplication and minimal
inflammatory response
↓
Extension of organisms( within 4-6 weeks after inhalation) into
the bloodstream from the regional nodes
↓
Cell mediated immunity / hypersensitivity reaction
↓
Development of clinical infection
Chest x-rays: Multi nodular
infiltrate above or behind
the clavicle with or without
pleural effusion unilaterally
or bilaterally.
• Cultures will reveal the
presence of mycobacterium
tuberculosis
• Patients stay infectious for
as long as the bacilli are
excreted in the sputum
Skin test. PPD (purified protein
derivative) antigens are injected
intradermally. A positive reaction
is a helpful adjunct in diagnosis.
Tuberculin test positivity
indicated hypersentivity to
bacterial protein
According to their clinical utility the drugs are:
 First line drugs : High antitubercular efficacy and low
toxicity which are used routinely.
 Second line drugs: Either low antitubercular efficacy
or high toxicity or both, used in special
circumstances only.
First line drugs include:
-ISONIAZIDE
- PYRAZINAMIDE
- ETHAMBUTOL
-RIFAMPICIN
-STREPTOMYCIN
HIGH EFFICACY AND LOW TOXICITY
Second line drugs include:
-THIACETAZONE
-CAPREOMYCIN
-P-AMINOSALICYLIC ACID
-ETHIONAMIDE
-CYCLOSERINE
-KANAMYCIN
-AMIKACIN
LOW EFFICACY AND HIGH TOXICITY
NEWER SECOND LINE DRUGS:
 Flouroquinolones are active against M.tuberculosis.
Ciproflaxacin,
Oflaxacin,
 Newer macrolides and some rifampin congeners are
the recent additions.
Clarithromycin,
Azithromycin,
Rifabutin.
 Considered the drug of choice for the
chemotherapy of TB. discovered in 1945 a
hydrazide of isonicotonic acid
 bacteriostatic for resting bacilli,
 bactericidal for growing bacilli.
 Most active anti-tb drug.
 Dose:5mg/kg daily
 It inhibits cell wall sythesis or mycolic acid synthesis.
 Important assets are
-potency
-infrequent toxicity
-low cost
 Useful for tb meningitis.
 Effective for both extra cellular & intracellular tb.
 If combined with other drug it has good resistance
preventing action.
ISONIAZID
Kat G( catalase peroxidase
in mycobacteria)
Active INH
AcpM & Kas AcpM- Acyl Carrier protein
KasA ( ß ketoAcyl Carrier protein
synthetase)
Block Mycolic Acid Synthesis
I. Rash
II. Peripheral Neuropathy
III. Hepatitis
IV. Transient loss of Memory
V. Seizure
VI. Pleural effusion
VII. Arthralgia
 Semisynth. deri of Rifamycin B-from St.meditarranei.
 Acts both extra & intracellularly.
 Bactericidal efficacy ≈ INH
&>any other 1st line drug
 Analogue of RIFAMPIN is RIFABUTIN.
obtained from Rifamycin S.
Dose: 10mg/kg daily or 2-3 times weekly
 D.N.A

RIFAMPIN
 DNA dependent R.N.A.polymerase
R.N.A

Protein Syn.

Cell multiplication
Rifampin bind to β S.U of D.D.R.P

Drug –Enz Complex

Supression of chain initiation
 Hepatitis, a major adverse effect.
 Respiratory syndrome: breathlessness.
 Purpura, haemolysis, shock and renal failure.
 Cutaneous syndrome : flushing, pruritis + rash.
 Flu like syndrome : fever, headache, bone pain.
 Synthetic analogue of Nicotinamide.
 Though weakly tuberculocidal

More active in acidic medium.
 Highly effective during 1st 2months.
 More effective against Slow Growing.
 Active both intra & extracellularly.
 Dose : 20-25mg/kg daily
 Pyrazinamide
Mycobacterial Pyrazinamidase
Pyrazinoic Acid
Inhibits Mycolic Acid Synthesis
Adverse effects:
 Arthralgia
 Flushing
 Rashes
 Fever
 loss of diabetes control
 Hepatotoxicity
 Rapid Growers are more susceptible.
 Prevent the emergence of Resistant bacilli.
 C/I ; Cr. Clearance <50ml/min
Doses of Ethambutol : 15mg/kg/day
Mycobact. Arabinosyl Transferase

ETHAMBUTOL

Polymerisation reaction of
Arabinoglycan

Essential component of Myco.Cellwall
 Loss of visual acuity
 Color blindness
 Field Defect
 Early recognition &stoppage of drug-
visual toxicities is largely reversible
Contra-indication ;In children <6yrs
a) they are unable to report early.
b) may not permit the assessment of
red green color blindness discrimination
  Renal uric acid excretion
Hyperuricemia
 Joint Pain
 First drug used for the treatment of TB.
 It is aminoglycoside antibiotic.
 It is tuberculocidal .
 It acts only on extracelluluar bacilli.
 Limitation of its use
i)dose related toxicity
ii)development of resistant org.
iii)pt compliance is poor due to i. m
 acts by protein synthesis inhibitor and decreases the
fidelity mRNA and garbles the message, leads to nonsense
proteins.
 Streptomycin only binds to the 30s subunit.
 Dose: 15mg/kg 3 times weekly for first 2-3 months for
severe disease
 H1 receptor blockers cause ototoxicity, with other
aminoglycosides, diuretics and vancomycin
SIDE EFFECTS:
 OTOTOXICITY-drugs get conc. In labrynthine fluid,
both vestibular & cochlear damage
 NEPHROTOXICITY
 PARALYSIS
 Sterile abscess at the inj. site
 Aminoglycosides: least effective and more toxic
Capreomycin - Viomycin – Kanamycin
Adverse effects:
 These drugs are: Nephrotoxic will cause Proteinuria,
Hematuria, Nitrogen metabolism, and Electrolyte
disturbances
However effect is reversible when drug is stopped
 Capreomycin has replaced viomycin because of less toxic
effects, but all three drugs have the same effects.
 Can cause CNS disturbances
 Therapeutic States :
Cycloserine should be used when re-treatment is
necessary or when the micro-organism is resistant to the
other drugs.
 It must be given in combination with other anti-
tuberculosis drugs.
 Dose: 500 mg to 1g per day
 Mechanism of Action :
An analog of D- alanine synthetase, will block bacterial
cell wall synthesis.
 These are first anti tubercular drugs.
 It is a tuberculostatic drug.
 Low efficacy drug.
 Side effects:
hepatitis,
optic neuritis,
mental disturbences
impotence
Dose: 150mg per day
 PAS is a tuberculostatic and one of least active drugs.
 It inhibits denovo folate synthesis.
 PAS is completely absorbed by oral route and
distributed all over .
 Dose : 150 mg/kg/day
 Patient acceptability of PAS is poor.
 Adverse effects ;
Rashes, fever, liver dysfunction
Chemotherapy
DOTS:
To control tuberculosis requires:
 Effective, inexpensive, simple and standardised technology.
The success of the DOTS strategy depends on:
 Government commitment to a national tuberculosis
programme.
 Case detection –finding by smear microscopy examination
of TB susceptible in general health services.
 Regular uninterrupted supply of essential anti-TB drugs.
 Monitoring system for programme supervised and
evaluation.
Short Course Chemotherapy:
 These are regimens of 6-9 month duration.
 All regimens have an initial intensive phase lasting 2-3
months to kill the TB bacilli and afford symptomatic
relief.
 This is followed by continuation phase for 4-6 months
so that relapse does not occur.
Type of patient Duration of
treatment
Regimen
Category-1
1.New sputum positive
2.Seriously ill, sputum
negative, Pulmonary
3.Seriously ill
Intensive
phase(2months)
Continuation
phase(4months)
INH+RMP+ETB+PZA
INH+RMP
Category-2
Retreatment group
1.Relapse
2.Treatment failure
Intensive
phase(3months)
Continuation
phase(5months)
INH+RMP+ETB+PZA
INH+RMP+ETB
Category-3
1.New smear negative
pulmonary
2.extrapulmonary
Intensive
phase(2months)
Continuation
phase(4months)
INH+RMP+PZA
INH+RMP
REGIMENS :
Multiple Drug Resistance(MDR):
 Resistance to both Isoniazid and Rifampin and number of
other anti-TB drugs . MDR-TB has a more rapid course
,(some die in 4-16 weeks).
 Treatment is difficult as second line drugs
are less efficacious, less convenient, more expensive and
toxic.
 Therapy depends on drugs used in earlier regimen, dosage
and regularity with which they have been taken.
 In India>200,000patients have been treated under DOTS
by early 2001 with cure rate of 75-80%.
 In other countries 80-93%cure rates have been obtained.
Chemotherapy
Treatment of TB is categorised by:
 Site of disease (pulmonary or extra pulmonary), its
severity: the bacillary load and acute threat to life are
taken into consideration.
 Sputum smear positivity/negativity :positive cases are
infectious.
 History of previous treatment: risk of drug resistance
is more in irregularly treated patients.
MARCH24
Thank u
For your Attention..

More Related Content

What's hot (20)

Antitubercular drugs
Antitubercular drugsAntitubercular drugs
Antitubercular drugs
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugs
 
Sulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhritiSulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhriti
 
Tuberculosis (2)dr.noha
Tuberculosis (2)dr.nohaTuberculosis (2)dr.noha
Tuberculosis (2)dr.noha
 
Antileprotic drugs - drdhriti
Antileprotic drugs - drdhritiAntileprotic drugs - drdhriti
Antileprotic drugs - drdhriti
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugs
 
Anti tb drugs
Anti tb drugsAnti tb drugs
Anti tb drugs
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Antimalarial drugs
Antimalarial drugsAntimalarial drugs
Antimalarial drugs
 
Cephalosporin Antibiotics
Cephalosporin AntibioticsCephalosporin Antibiotics
Cephalosporin Antibiotics
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
Isoniazid, Rifampicin, Pyrazinamide and EthambutolIsoniazid, Rifampicin, Pyrazinamide and Ethambutol
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones
 
Chemotherapy of Tuberculosis
Chemotherapy of TuberculosisChemotherapy of Tuberculosis
Chemotherapy of Tuberculosis
 
Drugs for Bronchial Asthma
Drugs for Bronchial AsthmaDrugs for Bronchial Asthma
Drugs for Bronchial Asthma
 
Pharmacotherapy of Tuberculosis
Pharmacotherapy of TuberculosisPharmacotherapy of Tuberculosis
Pharmacotherapy of Tuberculosis
 

Viewers also liked

Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentationRRR784
 
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku JosephBasic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku JosephDr.Tinku Joseph
 
Pulmmonary tuberculosis
Pulmmonary tuberculosisPulmmonary tuberculosis
Pulmmonary tuberculosisErasto Umoja
 
Review on microbiology and pathophysiology of tuberculosis
Review on microbiology and pathophysiology of tuberculosisReview on microbiology and pathophysiology of tuberculosis
Review on microbiology and pathophysiology of tuberculosisdocpiash
 
On the ground experiences & challenges of a connected diagnostics GxAlert in ...
On the ground experiences & challenges of a connected diagnostics GxAlert in ...On the ground experiences & challenges of a connected diagnostics GxAlert in ...
On the ground experiences & challenges of a connected diagnostics GxAlert in ...SystemOne
 
Anti Tubercular drugs
Anti Tubercular drugsAnti Tubercular drugs
Anti Tubercular drugsAditya Sarin
 
Cost Effective Technology for Effective and Rapid TB Response in Nigeria
Cost Effective Technology for Effective and Rapid TB Response in Nigeria Cost Effective Technology for Effective and Rapid TB Response in Nigeria
Cost Effective Technology for Effective and Rapid TB Response in Nigeria SystemOne
 
Lessons learned in implementing community tb prevention programme in south we...
Lessons learned in implementing community tb prevention programme in south we...Lessons learned in implementing community tb prevention programme in south we...
Lessons learned in implementing community tb prevention programme in south we...John Bako
 
Training on Tuberculosis & Its Treatment
Training on Tuberculosis & Its TreatmentTraining on Tuberculosis & Its Treatment
Training on Tuberculosis & Its TreatmentDr. ANSHU GOKARN
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPnavinthakkar
 
Treatment of spinal tuberculosis
Treatment of spinal tuberculosisTreatment of spinal tuberculosis
Treatment of spinal tuberculosisKshitij Chaudhary
 
Impact of health education on tuberculosis drug adherence
Impact of health education on tuberculosis drug adherenceImpact of health education on tuberculosis drug adherence
Impact of health education on tuberculosis drug adherenceSkillet Tony
 
Tuberculosis Pathogenesis
Tuberculosis PathogenesisTuberculosis Pathogenesis
Tuberculosis PathogenesisDr Hemanth Naik
 
4. chronic inflammation granulomatous inflammation -dr. sinhasan- mdzah
4. chronic inflammation  granulomatous inflammation -dr. sinhasan- mdzah4. chronic inflammation  granulomatous inflammation -dr. sinhasan- mdzah
4. chronic inflammation granulomatous inflammation -dr. sinhasan- mdzahkciapm
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonDr.Sohel Memon
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationThe CRUDEM Foundation
 

Viewers also liked (20)

Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentation
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku JosephBasic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Pulmmonary tuberculosis
Pulmmonary tuberculosisPulmmonary tuberculosis
Pulmmonary tuberculosis
 
Review on microbiology and pathophysiology of tuberculosis
Review on microbiology and pathophysiology of tuberculosisReview on microbiology and pathophysiology of tuberculosis
Review on microbiology and pathophysiology of tuberculosis
 
On the ground experiences & challenges of a connected diagnostics GxAlert in ...
On the ground experiences & challenges of a connected diagnostics GxAlert in ...On the ground experiences & challenges of a connected diagnostics GxAlert in ...
On the ground experiences & challenges of a connected diagnostics GxAlert in ...
 
Anti Tubercular drugs
Anti Tubercular drugsAnti Tubercular drugs
Anti Tubercular drugs
 
Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
 
Cost Effective Technology for Effective and Rapid TB Response in Nigeria
Cost Effective Technology for Effective and Rapid TB Response in Nigeria Cost Effective Technology for Effective and Rapid TB Response in Nigeria
Cost Effective Technology for Effective and Rapid TB Response in Nigeria
 
Lessons learned in implementing community tb prevention programme in south we...
Lessons learned in implementing community tb prevention programme in south we...Lessons learned in implementing community tb prevention programme in south we...
Lessons learned in implementing community tb prevention programme in south we...
 
Training on Tuberculosis & Its Treatment
Training on Tuberculosis & Its TreatmentTraining on Tuberculosis & Its Treatment
Training on Tuberculosis & Its Treatment
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCP
 
Treatment of spinal tuberculosis
Treatment of spinal tuberculosisTreatment of spinal tuberculosis
Treatment of spinal tuberculosis
 
Impact of health education on tuberculosis drug adherence
Impact of health education on tuberculosis drug adherenceImpact of health education on tuberculosis drug adherence
Impact of health education on tuberculosis drug adherence
 
Tuberculosis Pathogenesis
Tuberculosis PathogenesisTuberculosis Pathogenesis
Tuberculosis Pathogenesis
 
4. chronic inflammation granulomatous inflammation -dr. sinhasan- mdzah
4. chronic inflammation  granulomatous inflammation -dr. sinhasan- mdzah4. chronic inflammation  granulomatous inflammation -dr. sinhasan- mdzah
4. chronic inflammation granulomatous inflammation -dr. sinhasan- mdzah
 
Tuberculosis Teaching Basics
Tuberculosis Teaching BasicsTuberculosis Teaching Basics
Tuberculosis Teaching Basics
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel Memon
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM Foundation
 

Similar to Tuberculosis

CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxSamuelAgboola11
 
Anti tuberculosis
Anti tuberculosisAnti tuberculosis
Anti tuberculosisZainab&Sons
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisRavi Kiran
 
anti TB and othes.pptx
anti TB and othes.pptxanti TB and othes.pptx
anti TB and othes.pptxDerejeTsegaye8
 
TB and Leprosy.pptx
TB and Leprosy.pptxTB and Leprosy.pptx
TB and Leprosy.pptxsapnabohra2
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.pptAbwoneKenneth
 
Pathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisPathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisSoujanya Pharm.D
 
Tuberculosis& its management
Tuberculosis& its managementTuberculosis& its management
Tuberculosis& its managementraj kumar
 
21 Antitubercular Agents Updates (pharmacology on line classes)
21 Antitubercular Agents Updates (pharmacology on line classes)21 Antitubercular Agents Updates (pharmacology on line classes)
21 Antitubercular Agents Updates (pharmacology on line classes)jben501
 
Tuberculosis pharmacotherapy
Tuberculosis pharmacotherapyTuberculosis pharmacotherapy
Tuberculosis pharmacotherapysachin panwar
 
Management of multi drug resistant tuberculosis
Management of multi drug resistant tuberculosisManagement of multi drug resistant tuberculosis
Management of multi drug resistant tuberculosisPharmacology Profession
 
Pulmonary Tuberculosis
Pulmonary TuberculosisPulmonary Tuberculosis
Pulmonary TuberculosisLouie Ray
 

Similar to Tuberculosis (20)

Anti tuberular agents
Anti tuberular agentsAnti tuberular agents
Anti tuberular agents
 
Anti tuberculosis drugs
Anti tuberculosis drugsAnti tuberculosis drugs
Anti tuberculosis drugs
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
 
TB.pptx
TB.pptxTB.pptx
TB.pptx
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Pulmonary Tuberculosis
Pulmonary TuberculosisPulmonary Tuberculosis
Pulmonary Tuberculosis
 
Anti tuberculosis
Anti tuberculosisAnti tuberculosis
Anti tuberculosis
 
Anti tb drugs
Anti tb drugsAnti tb drugs
Anti tb drugs
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosis
 
anti TB and othes.pptx
anti TB and othes.pptxanti TB and othes.pptx
anti TB and othes.pptx
 
TB and Leprosy.pptx
TB and Leprosy.pptxTB and Leprosy.pptx
TB and Leprosy.pptx
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.ppt
 
Pathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisPathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosis
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
tuberulosis ppt
tuberulosis ppttuberulosis ppt
tuberulosis ppt
 
Tuberculosis& its management
Tuberculosis& its managementTuberculosis& its management
Tuberculosis& its management
 
21 Antitubercular Agents Updates (pharmacology on line classes)
21 Antitubercular Agents Updates (pharmacology on line classes)21 Antitubercular Agents Updates (pharmacology on line classes)
21 Antitubercular Agents Updates (pharmacology on line classes)
 
Tuberculosis pharmacotherapy
Tuberculosis pharmacotherapyTuberculosis pharmacotherapy
Tuberculosis pharmacotherapy
 
Management of multi drug resistant tuberculosis
Management of multi drug resistant tuberculosisManagement of multi drug resistant tuberculosis
Management of multi drug resistant tuberculosis
 
Pulmonary Tuberculosis
Pulmonary TuberculosisPulmonary Tuberculosis
Pulmonary Tuberculosis
 

More from velspharmd

Crossed Aldol Condensation
Crossed Aldol CondensationCrossed Aldol Condensation
Crossed Aldol Condensationvelspharmd
 
Anxiety Disorders
Anxiety DisordersAnxiety Disorders
Anxiety Disordersvelspharmd
 
Orchitis-Case Study
Orchitis-Case StudyOrchitis-Case Study
Orchitis-Case Studyvelspharmd
 
Pain management vels
Pain management velsPain management vels
Pain management velsvelspharmd
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Studyvelspharmd
 
Nicotine addiction
Nicotine addictionNicotine addiction
Nicotine addictionvelspharmd
 
Thyroid function tests
Thyroid function testsThyroid function tests
Thyroid function testsvelspharmd
 
Role of atorvastatin
Role of atorvastatinRole of atorvastatin
Role of atorvastatinvelspharmd
 
Methyl alchohol poisoning
Methyl alchohol poisoningMethyl alchohol poisoning
Methyl alchohol poisoningvelspharmd
 
Renal function tests
Renal function testsRenal function tests
Renal function testsvelspharmd
 
Pulmonary function test
Pulmonary function testPulmonary function test
Pulmonary function testvelspharmd
 
Tests associated with cardiac disorders
Tests associated with cardiac disorders Tests associated with cardiac disorders
Tests associated with cardiac disorders velspharmd
 
Thyroid function tests
Thyroid function testsThyroid function tests
Thyroid function testsvelspharmd
 
GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASEGASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASEvelspharmd
 
ANXIETY DISORDERS
ANXIETY DISORDERSANXIETY DISORDERS
ANXIETY DISORDERSvelspharmd
 
INFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASEINFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASEvelspharmd
 
Food poisoning
Food poisoningFood poisoning
Food poisoningvelspharmd
 

More from velspharmd (20)

Crossed Aldol Condensation
Crossed Aldol CondensationCrossed Aldol Condensation
Crossed Aldol Condensation
 
Anxiety Disorders
Anxiety DisordersAnxiety Disorders
Anxiety Disorders
 
Orchitis-Case Study
Orchitis-Case StudyOrchitis-Case Study
Orchitis-Case Study
 
simeprevir
simeprevirsimeprevir
simeprevir
 
Pain management vels
Pain management velsPain management vels
Pain management vels
 
Tivicay®
Tivicay®Tivicay®
Tivicay®
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
 
Nicotine addiction
Nicotine addictionNicotine addiction
Nicotine addiction
 
Thyroid function tests
Thyroid function testsThyroid function tests
Thyroid function tests
 
Role of atorvastatin
Role of atorvastatinRole of atorvastatin
Role of atorvastatin
 
Methyl alchohol poisoning
Methyl alchohol poisoningMethyl alchohol poisoning
Methyl alchohol poisoning
 
Renal function tests
Renal function testsRenal function tests
Renal function tests
 
Pulmonary function test
Pulmonary function testPulmonary function test
Pulmonary function test
 
Tests associated with cardiac disorders
Tests associated with cardiac disorders Tests associated with cardiac disorders
Tests associated with cardiac disorders
 
Thyroid function tests
Thyroid function testsThyroid function tests
Thyroid function tests
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
GASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASEGASTROESOPHAGEAL REFLUX DISEASE
GASTROESOPHAGEAL REFLUX DISEASE
 
ANXIETY DISORDERS
ANXIETY DISORDERSANXIETY DISORDERS
ANXIETY DISORDERS
 
INFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASEINFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASE
 
Food poisoning
Food poisoningFood poisoning
Food poisoning
 

Recently uploaded

The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxraviapr7
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 

Recently uploaded (20)

The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptx
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 

Tuberculosis

  • 3.  Tuberculosis or TB is a common and often deadly infectious disease caused by mycobacteria, usually Mycobacterium tuberculosis in humans.  Tuberculosis usually attacks the lungs but can also affect other parts of the body.  The classic symptoms are a chronic cough with blood-tinged sputum, fever, night sweats, and weight loss.
  • 4.  The primary cause of TB, Mycobacterium tuberculosis , is a small aerobic non-motile bacillus.  The M. tuberculosis complex includes four other TB- causing mycobacteria: M. bovis, M. africanum, M. canetti and M. microti.  M. africanum is not widespread, but in parts of Africa it is a significant cause of tuberculosis.
  • 5.  It is currently estimated that 1/2 of the world's population (3.1 billion) is infected with Mycobacterium tuberculosis. Mycobacterium avium complex is associated with AIDS related TB.  The proportion of people who become sick with tuberculosis each year is stable or falling worldwide but, because of population growth, the absolute number of new cases is still increasing. EPIDEMIOLOGY:
  • 6.  In 2007 there were an estimated 13.7 million chronic active cases, 9.3 million new cases, and 1.8 million deaths, mostly in developing countries.  The distribution of tuberculosis is not uniform across the globe; about 80% of the population in many Asian and African countries test positive in tuberculin tests, while only 5-10% of the US population test positive.
  • 7. Per 1,000,00 10 - 24 < 10 25 - 49 50 - 99 100 - 299 300 or more No estimate Highest estimated TB rates per capita were in Africa
  • 8.  Pulmonary tuberculosis is a disease of respiratory transmission, Patients with the active disease (bacilli) expel them into the air by:  coughing,  sneezing,  shouting,  or any other way that will expel bacilli into the air Transmission is dependent on closeness and time of contact Transmission:
  • 9.  Once inhaled by a tuberculin free person, the bacilli multiply 4 -6 weeks and spreads throughout the body. The bacilli implant in areas of high partial pressure of oxygen:  lung  renal cortex  reticuloendothelial system
  • 10.  When the disease becomes active, 75% of the cases are pulmonary TB, that is, TB in the lungs.  Symptoms include chest pain, coughing up blood, and a productive, prolonged cough for more than three weeks.  Systemic symptoms include fever, chills, night sweats, appetite loss, weight loss, pallor, and often a tendency to fatigue very easily.
  • 11.  In the other 25% of active cases, the infection moves from the lungs, causing other kinds of TB, collectively denoted extrapulmonary tuberculosis. This occurs more commonly in immunosuppressed persons and young children.  Extrapulmonary infection sites include the pleura in tuberculosis pleurisy, the central nervous system in meningitis, the lymphatic system in scrofula of the neck, the genitourinary system in urogenital tuberculosis, and bones and joints in Pott's disease of the spine.
  • 13. Infection via inhalation of droplet nuclei. ↓ Transport of bacilli to terminal alveoli (especially lower segments of lungs) ↓ Ingestion of organisms by macrophages followed by multiplication within macrophages ↓ Transport of organisms to regional lymph nodes by infected macrophages with continue multiplication and minimal inflammatory response
  • 14. ↓ Extension of organisms( within 4-6 weeks after inhalation) into the bloodstream from the regional nodes ↓ Cell mediated immunity / hypersensitivity reaction ↓ Development of clinical infection
  • 15. Chest x-rays: Multi nodular infiltrate above or behind the clavicle with or without pleural effusion unilaterally or bilaterally.
  • 16. • Cultures will reveal the presence of mycobacterium tuberculosis • Patients stay infectious for as long as the bacilli are excreted in the sputum
  • 17. Skin test. PPD (purified protein derivative) antigens are injected intradermally. A positive reaction is a helpful adjunct in diagnosis. Tuberculin test positivity indicated hypersentivity to bacterial protein
  • 18. According to their clinical utility the drugs are:  First line drugs : High antitubercular efficacy and low toxicity which are used routinely.  Second line drugs: Either low antitubercular efficacy or high toxicity or both, used in special circumstances only.
  • 19. First line drugs include: -ISONIAZIDE - PYRAZINAMIDE - ETHAMBUTOL -RIFAMPICIN -STREPTOMYCIN HIGH EFFICACY AND LOW TOXICITY
  • 20. Second line drugs include: -THIACETAZONE -CAPREOMYCIN -P-AMINOSALICYLIC ACID -ETHIONAMIDE -CYCLOSERINE -KANAMYCIN -AMIKACIN LOW EFFICACY AND HIGH TOXICITY
  • 21. NEWER SECOND LINE DRUGS:  Flouroquinolones are active against M.tuberculosis. Ciproflaxacin, Oflaxacin,  Newer macrolides and some rifampin congeners are the recent additions. Clarithromycin, Azithromycin, Rifabutin.
  • 22.  Considered the drug of choice for the chemotherapy of TB. discovered in 1945 a hydrazide of isonicotonic acid  bacteriostatic for resting bacilli,  bactericidal for growing bacilli.
  • 23.  Most active anti-tb drug.  Dose:5mg/kg daily  It inhibits cell wall sythesis or mycolic acid synthesis.  Important assets are -potency -infrequent toxicity -low cost  Useful for tb meningitis.  Effective for both extra cellular & intracellular tb.  If combined with other drug it has good resistance preventing action.
  • 24. ISONIAZID Kat G( catalase peroxidase in mycobacteria) Active INH AcpM & Kas AcpM- Acyl Carrier protein KasA ( ß ketoAcyl Carrier protein synthetase) Block Mycolic Acid Synthesis
  • 25. I. Rash II. Peripheral Neuropathy III. Hepatitis IV. Transient loss of Memory V. Seizure VI. Pleural effusion VII. Arthralgia
  • 26.  Semisynth. deri of Rifamycin B-from St.meditarranei.  Acts both extra & intracellularly.  Bactericidal efficacy ≈ INH &>any other 1st line drug  Analogue of RIFAMPIN is RIFABUTIN. obtained from Rifamycin S. Dose: 10mg/kg daily or 2-3 times weekly
  • 27.  D.N.A  RIFAMPIN  DNA dependent R.N.A.polymerase R.N.A  Protein Syn.  Cell multiplication Rifampin bind to β S.U of D.D.R.P  Drug –Enz Complex  Supression of chain initiation
  • 28.  Hepatitis, a major adverse effect.  Respiratory syndrome: breathlessness.  Purpura, haemolysis, shock and renal failure.  Cutaneous syndrome : flushing, pruritis + rash.  Flu like syndrome : fever, headache, bone pain.
  • 29.  Synthetic analogue of Nicotinamide.  Though weakly tuberculocidal  More active in acidic medium.  Highly effective during 1st 2months.  More effective against Slow Growing.  Active both intra & extracellularly.  Dose : 20-25mg/kg daily
  • 30.  Pyrazinamide Mycobacterial Pyrazinamidase Pyrazinoic Acid Inhibits Mycolic Acid Synthesis
  • 31. Adverse effects:  Arthralgia  Flushing  Rashes  Fever  loss of diabetes control  Hepatotoxicity
  • 32.  Rapid Growers are more susceptible.  Prevent the emergence of Resistant bacilli.  C/I ; Cr. Clearance <50ml/min Doses of Ethambutol : 15mg/kg/day
  • 33. Mycobact. Arabinosyl Transferase  ETHAMBUTOL  Polymerisation reaction of Arabinoglycan  Essential component of Myco.Cellwall
  • 34.  Loss of visual acuity  Color blindness  Field Defect  Early recognition &stoppage of drug- visual toxicities is largely reversible Contra-indication ;In children <6yrs a) they are unable to report early. b) may not permit the assessment of red green color blindness discrimination   Renal uric acid excretion Hyperuricemia  Joint Pain
  • 35.  First drug used for the treatment of TB.  It is aminoglycoside antibiotic.  It is tuberculocidal .  It acts only on extracelluluar bacilli.  Limitation of its use i)dose related toxicity ii)development of resistant org. iii)pt compliance is poor due to i. m
  • 36.  acts by protein synthesis inhibitor and decreases the fidelity mRNA and garbles the message, leads to nonsense proteins.  Streptomycin only binds to the 30s subunit.  Dose: 15mg/kg 3 times weekly for first 2-3 months for severe disease  H1 receptor blockers cause ototoxicity, with other aminoglycosides, diuretics and vancomycin
  • 37. SIDE EFFECTS:  OTOTOXICITY-drugs get conc. In labrynthine fluid, both vestibular & cochlear damage  NEPHROTOXICITY  PARALYSIS  Sterile abscess at the inj. site
  • 38.  Aminoglycosides: least effective and more toxic Capreomycin - Viomycin – Kanamycin Adverse effects:  These drugs are: Nephrotoxic will cause Proteinuria, Hematuria, Nitrogen metabolism, and Electrolyte disturbances However effect is reversible when drug is stopped  Capreomycin has replaced viomycin because of less toxic effects, but all three drugs have the same effects.
  • 39.  Can cause CNS disturbances  Therapeutic States : Cycloserine should be used when re-treatment is necessary or when the micro-organism is resistant to the other drugs.  It must be given in combination with other anti- tuberculosis drugs.  Dose: 500 mg to 1g per day  Mechanism of Action : An analog of D- alanine synthetase, will block bacterial cell wall synthesis.
  • 40.  These are first anti tubercular drugs.  It is a tuberculostatic drug.  Low efficacy drug.  Side effects: hepatitis, optic neuritis, mental disturbences impotence Dose: 150mg per day
  • 41.  PAS is a tuberculostatic and one of least active drugs.  It inhibits denovo folate synthesis.  PAS is completely absorbed by oral route and distributed all over .  Dose : 150 mg/kg/day  Patient acceptability of PAS is poor.  Adverse effects ; Rashes, fever, liver dysfunction
  • 42. Chemotherapy DOTS: To control tuberculosis requires:  Effective, inexpensive, simple and standardised technology. The success of the DOTS strategy depends on:  Government commitment to a national tuberculosis programme.  Case detection –finding by smear microscopy examination of TB susceptible in general health services.  Regular uninterrupted supply of essential anti-TB drugs.  Monitoring system for programme supervised and evaluation.
  • 43. Short Course Chemotherapy:  These are regimens of 6-9 month duration.  All regimens have an initial intensive phase lasting 2-3 months to kill the TB bacilli and afford symptomatic relief.  This is followed by continuation phase for 4-6 months so that relapse does not occur.
  • 44. Type of patient Duration of treatment Regimen Category-1 1.New sputum positive 2.Seriously ill, sputum negative, Pulmonary 3.Seriously ill Intensive phase(2months) Continuation phase(4months) INH+RMP+ETB+PZA INH+RMP Category-2 Retreatment group 1.Relapse 2.Treatment failure Intensive phase(3months) Continuation phase(5months) INH+RMP+ETB+PZA INH+RMP+ETB Category-3 1.New smear negative pulmonary 2.extrapulmonary Intensive phase(2months) Continuation phase(4months) INH+RMP+PZA INH+RMP REGIMENS :
  • 45. Multiple Drug Resistance(MDR):  Resistance to both Isoniazid and Rifampin and number of other anti-TB drugs . MDR-TB has a more rapid course ,(some die in 4-16 weeks).  Treatment is difficult as second line drugs are less efficacious, less convenient, more expensive and toxic.  Therapy depends on drugs used in earlier regimen, dosage and regularity with which they have been taken.  In India>200,000patients have been treated under DOTS by early 2001 with cure rate of 75-80%.  In other countries 80-93%cure rates have been obtained.
  • 46. Chemotherapy Treatment of TB is categorised by:  Site of disease (pulmonary or extra pulmonary), its severity: the bacillary load and acute threat to life are taken into consideration.  Sputum smear positivity/negativity :positive cases are infectious.  History of previous treatment: risk of drug resistance is more in irregularly treated patients.
  • 48. Thank u For your Attention..